Growth Perspectives: Key Highlights from DCAT 2024
Frost & Sullivan
APRIL 3, 2024
Wuxi STA expanded its partnership with Ark Biopharmaceutical for the commercial supply of Ziresovir, a first-in-class oral antiviral for respiratory syncytial virus, which has completed the phase III clinical trial globally, for which a New Drug Application has been accepted and granted Priority Review by the China NMPA.
59 
Let's personalize your content